331 related articles for article (PubMed ID: 22123689)
21. A novel intravaginal ring to prevent HIV-1, HSV-2, HPV, and unintended pregnancy.
Ugaonkar SR; Wesenberg A; Wilk J; Seidor S; Mizenina O; Kizima L; Rodriguez A; Zhang S; Levendosky K; Kenney J; Aravantinou M; Derby N; Grasperge B; Gettie A; Blanchard J; Kumar N; Roberts K; Robbiani M; Fernández-Romero JA; Zydowsky TM
J Control Release; 2015 Sep; 213():57-68. PubMed ID: 26091920
[TBL] [Abstract][Full Text] [Related]
22. Susceptibility to genital herpes as a biomarker predictive of increased HIV risk: expansion of a murine model of microbicide safety.
Wilson SS; Cheshenko N; Fakioglu E; Mesquita PM; Keller MJ; Herold BC
Antivir Ther; 2009; 14(8):1113-24. PubMed ID: 20032541
[TBL] [Abstract][Full Text] [Related]
23. Durable protection from vaginal simian-human immunodeficiency virus infection in macaques by tenofovir gel and its relationship to drug levels in tissue.
Dobard C; Sharma S; Martin A; Pau CP; Holder A; Kuklenyik Z; Lipscomb J; Hanson DL; Smith J; Novembre FJ; García-Lerma JG; Heneine W
J Virol; 2012 Jan; 86(2):718-25. PubMed ID: 22072766
[TBL] [Abstract][Full Text] [Related]
24. Tenofovir Gel for Prevention of Herpes Simplex Virus Type 2 Acquisition: Findings From the VOICE Trial.
Marrazzo JM; Rabe L; Kelly C; Richardson B; Deal C; Schwartz JL; Chirenje ZM; Piper J; Morrow RA; Hendrix CW; Marzinke MA; Hillier SL;
J Infect Dis; 2019 May; 219(12):1940-1947. PubMed ID: 30753642
[TBL] [Abstract][Full Text] [Related]
25. RMP-02/MTN-006: A phase 1 rectal safety, acceptability, pharmacokinetic, and pharmacodynamic study of tenofovir 1% gel compared with oral tenofovir disoproxil fumarate.
Anton PA; Cranston RD; Kashuba A; Hendrix CW; Bumpus NN; Richardson-Harman N; Elliott J; Janocko L; Khanukhova E; Dennis R; Cumberland WG; Ju C; Carballo-Diéguez A; Mauck C; McGowan I
AIDS Res Hum Retroviruses; 2012 Nov; 28(11):1412-21. PubMed ID: 22943559
[TBL] [Abstract][Full Text] [Related]
26. Tenofovir Gel for the Prevention of Herpes Simplex Virus Type 2 Infection.
Abdool Karim SS; Abdool Karim Q; Kharsany AB; Baxter C; Grobler AC; Werner L; Kashuba A; Mansoor LE; Samsunder N; Mindel A; Gengiah TN;
N Engl J Med; 2015 Aug; 373(6):530-9. PubMed ID: 26244306
[TBL] [Abstract][Full Text] [Related]
27. Randomized, placebo controlled phase I trial of safety, pharmacokinetics, pharmacodynamics and acceptability of tenofovir and tenofovir plus levonorgestrel vaginal rings in women.
Thurman AR; Schwartz JL; Brache V; Clark MR; McCormick T; Chandra N; Marzinke MA; Stanczyk FZ; Dezzutti CS; Hillier SL; Herold BC; Fichorova R; Asin SN; Rollenhagen C; Weiner D; Kiser P; Doncel GF
PLoS One; 2018; 13(6):e0199778. PubMed ID: 29953547
[TBL] [Abstract][Full Text] [Related]
28. Intravaginal ring delivery of tenofovir disoproxil fumarate for prevention of HIV and herpes simplex virus infection.
Mesquita PM; Rastogi R; Segarra TJ; Teller RS; Torres NM; Huber AM; Kiser PF; Herold BC
J Antimicrob Chemother; 2012 Jul; 67(7):1730-8. PubMed ID: 22467632
[TBL] [Abstract][Full Text] [Related]
29. Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: summary of pharmacokinetics and biological and virological effects.
Van Rompay KK; Durand-Gasselin L; Brignolo LL; Ray AS; Abel K; Cihlar T; Spinner A; Jerome C; Moore J; Kearney BP; Marthas ML; Reiser H; Bischofberger N
Antimicrob Agents Chemother; 2008 Sep; 52(9):3144-60. PubMed ID: 18573931
[TBL] [Abstract][Full Text] [Related]
30. Use of acyclovir for suppression of human immunodeficiency virus infection is not associated with genotypic evidence of herpes simplex virus type 2 resistance to acyclovir: analysis of specimens from three phase III trials.
Watson-Jones D; Wald A; Celum C; Lingappa J; Weiss HA; Changalucha J; Baisley K; Tanton C; Hayes RJ; Marshak JO; Gladden RG; Koelle DM
J Clin Microbiol; 2010 Oct; 48(10):3496-503. PubMed ID: 20702659
[TBL] [Abstract][Full Text] [Related]
31. Manufacturing scale-up of electrospun poly(vinyl alcohol) fibers containing tenofovir for vaginal drug delivery.
Krogstad EA; Woodrow KA
Int J Pharm; 2014 Nov; 475(1-2):282-91. PubMed ID: 25169075
[TBL] [Abstract][Full Text] [Related]
32. Increased Dapivirine tissue accumulation through vaginal film codelivery of dapivirine and Tenofovir.
Akil A; Devlin B; Cost M; Rohan LC
Mol Pharm; 2014 May; 11(5):1533-41. PubMed ID: 24693866
[TBL] [Abstract][Full Text] [Related]
33. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.
Abdool Karim Q; Abdool Karim SS; Frohlich JA; Grobler AC; Baxter C; Mansoor LE; Kharsany AB; Sibeko S; Mlisana KP; Omar Z; Gengiah TN; Maarschalk S; Arulappan N; Mlotshwa M; Morris L; Taylor D;
Science; 2010 Sep; 329(5996):1168-74. PubMed ID: 20643915
[TBL] [Abstract][Full Text] [Related]
34. Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission.
Patterson KB; Prince HA; Kraft E; Jenkins AJ; Shaheen NJ; Rooney JF; Cohen MS; Kashuba AD
Sci Transl Med; 2011 Dec; 3(112):112re4. PubMed ID: 22158861
[TBL] [Abstract][Full Text] [Related]
35. Tenofovir and tenofovir disoproxil fumarate pharmacokinetics from intravaginal rings.
Moss JA; Baum MM; Malone AM; Kennedy S; Kopin E; Nguyen C; Gilman J; Butkyavichene I; Willis RA; Vincent KL; Motamedi M; Smith TJ
AIDS; 2012 Mar; 26(6):707-10. PubMed ID: 22210639
[TBL] [Abstract][Full Text] [Related]
36. Quantitative evaluation of a hydrophilic matrix intravaginal ring for the sustained delivery of tenofovir.
Clark JT; Johnson TJ; Clark MR; Nebeker JS; Fabian J; Tuitupou AL; Ponnapalli S; Smith EM; Friend DR; Kiser PF
J Control Release; 2012 Oct; 163(2):240-8. PubMed ID: 22981701
[TBL] [Abstract][Full Text] [Related]
37. Natural substrate concentrations can modulate the prophylactic efficacy of nucleotide HIV reverse transcriptase inhibitors.
García-Lerma JG; Aung W; Cong ME; Zheng Q; Youngpairoj AS; Mitchell J; Holder A; Martin A; Kuklenyik S; Luo W; Lin CY; Hanson DL; Kersh E; Pau CP; Ray AS; Rooney JF; Lee WA; Heneine W
J Virol; 2011 Jul; 85(13):6610-7. PubMed ID: 21525346
[TBL] [Abstract][Full Text] [Related]
38. A phase 1 randomized placebo-controlled safety and pharmacokinetic trial of a tenofovir disoproxil fumarate vaginal ring.
Keller MJ; Mesquita PM; Marzinke MA; Teller R; Espinoza L; Atrio JM; Lo Y; Frank B; Srinivasan S; Fredricks DN; Rabe L; Anderson PL; Hendrix CW; Kiser PF; Herold BC
AIDS; 2016 Mar; 30(5):743-51. PubMed ID: 26605514
[TBL] [Abstract][Full Text] [Related]
39. HIV pre-exposure prophylaxis: mucosal tissue drug distribution of RT inhibitor Tenofovir and entry inhibitor Maraviroc in a humanized mouse model.
Veselinovic M; Yang KH; LeCureux J; Sykes C; Remling-Mulder L; Kashuba ADM; Akkina R
Virology; 2014 Sep; 464-465():253-263. PubMed ID: 25105490
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics of a multipurpose pod-intravaginal ring simultaneously delivering five drugs in an ovine model.
Moss JA; Malone AM; Smith TJ; Kennedy S; Nguyen C; Vincent KL; Motamedi M; Baum MM
Antimicrob Agents Chemother; 2013 Aug; 57(8):3994-7. PubMed ID: 23752507
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
